Atopic Dermatitis E-Book

Robert E. Kalb, MD

• Herausgeber: Integritas Communications
• Kategorie: Fachliteratur
• Sprache: Englisch

Seitenzahl: 62

Veröffentlichungsjahr: 2018

Beschreibung

The goal of this eHealth Source™ activity is to educate clinicians on atopic dermatitis pathoetiology, best practices in patient evaluations, and the clinical profiles of treatment options for moderate-to-severe disease, including a biologic therapy recently approved by the US Food and Drug Administration (FDA). With the overall goal of improving outcomes for patients with moderate-to-severe atopic dermatitis, this educational activity integrates published clinical data and the experience of expert faculty to provide actionable recommendations on individualizing care and improving patient-clinician communication.

Leseprobe

ATOPIC DERMATITIS

New Perspectives on Managing a Chronic Inflammatory Disease

Robert E. Kalb, MD and Jeffrey M. Weinberg, MD

¶

PRONOUN

© 2017-2018 Integritas Communications.

All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.

TABLE OF CONTENTS

Faculty: Robert E. Kalb, MD

Jeffrey M. Weinberg, MD

Preamble: Target Audience

Educational Objectives

Statement of Need/Program Overview

References

Physician Accreditation Statement

Physician Credit Designation

Global Contact Information

Instructions to Receive Credit

Fee Information & Refund/Cancellation Policy

Disclosure of Conflicts of Interest

Disclosure of Unlabeled Use

Disclaimer

Chapter 1: Causes and Consequences of Atopic Dermatitis

Outside-In vs Inside-Out Pathoetiology in Atopic Dermatitis

Key Clinical Highlights

References

Chapter 2: Evaluating Patients With Moderate-to-Severe Atopic Dermatitis

Identifying Atopic and Nonatopic Triggers

Assessing Clinical Outcomes in Patients with Diagnosed Atopic Dermatitis

Nonatopic Comorbidities Associated with Atopic Dermatitis

Key Clinical Highlights

References

Chapter 3: Current and Emerging Therapies for Atopic Dermatitis

Traditional Systemic Therapies for Atopic Dermatitis

Newer Targeted Therapies for Moderate-to-Severe Atopic Dermatitis

Key Clinical Highlights

References

Chapter 4: Individualizing Maintenance Therapy for Moderate-to-Severe Atopic Dermatitis

Addressing Comorbid Conditions

Considering Disease Phenotypes

Monitoring Treatment Outcomes With Topical and Systemic Therapies

Key Clinical Highlights

References

Chapter 5: Educating Patients and Improving Adherence

Encouraging Shared Decision-Making

Enhancing Treatment Adherence

Key Clinical Highlights

References

Atopic Dermatitis Clinical Resource Center™: Guidelines

Patient Resources

International Eczema Council

National Eczema Association

Clinical Assessment Tools

Eczema Area and Severity Index (EASI)

Investigator Global Assessment (IGA)

Scoring Atopic Dermatitis (SCORAD)

Management of difficult-to-treat atopic dermatitis.

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.

Translating atopic dermatitis management guidelines into practice for primary care providers.

Persistence of mild to moderate atopic dermatitis.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

Serious complications from Staphylococcal aureus in atopic dermatitis.

Anti-interleukin-31 receptor A antibody for atopic dermatitis.

Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults.

Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.

Eczema and cardiovascular risk factors in 2 US adult population studies.

Childhood atopic dermatitis and warts are associated with increased risk of infection: a US population-based study.

The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey.

CME Posttest

FACULTY

ROBERT E. KALB, MD

Clinical Professor, Department of Dermatology

SUNY at Buffalo School of Medicine and Biomedical Sciences

Buffalo Medical Group, P.C.

Buffalo, New York

Dr. Robert E. Kalb is a Clinical Professor of Dermatology at the State University of New York at Buffalo Jacobs School of Medicine and Biomedical Sciences, where his extensive teaching responsibilities include coordinating the fourth-year medical student dermatology rotation and working with dermatology and family medicine residents on a daily basis. He also chairs the dermatology department in private practice with the Buffalo Medical Group in Buffalo, New York.

Dr. Kalb obtained his medical degree cum laude from Downstate Health Science Center in Brooklyn, New York, in 1982 and then completed his residency in dermatology at the College of Physicians and Surgeons at Columbia University in New York.

Dr. Kalb has conducted numerous clinical trials investigating possible new treatments for psoriasis and other skin disorders. An invited lecturer at local, national, and international meetings, he has authored more than 60 articles in peer-reviewed journals.

JEFFREY M. WEINBERG, MD

Associate Clinical Professor of Dermatology

Icahn School of Medicine at Mount Sinai

New York, New York

Director, Division of Dermatology

Jamaica Hospital Medical Center

Richmond Hill, New York

Dr. Jeffrey M. Weinberg is an associate clinical professor of dermatology at the Mount Sinai School of Medicine in New York City. In addition, he is acting director of the Division of Dermatology at Jamaica Hospital Medical Center. Dr. Weinberg graduated from the University of Pennsylvania School of Medicine in Philadelphia and completed an internship in medicine at Columbia-Presbyterian Medical Center in New York City. He then completed a residency in dermatology at the University of Pennsylvania School of Medicine.

Dr. Weinberg is a Fellow of the American Academy of Dermatology, where he has served on several committees, and a member of the Dermatology Foundation. He is a diplomate of the American Board of Dermatology.

Dr. Weinberg is on the editorial board and is a Senior Editor of Cutis. He is also an Associate Editor of the Journal of the American Academy of Dermatology. He is a member of the Medical Board of the National Psoriasis Foundation. His clinical research encompasses a variety of dermatology-related topics, including studies of diagnostic methods in the evaluation of onychomycosis. He has been principal or co-investigator for several clinical trials. In addition, he has written or co-authored wnumerous articles for professional journals such as Cutis, the Journal of the American Academy of Dermatology, and Blood, as well as reviews, book chapters, and abstracts.

PREAMBLE

TARGET AUDIENCE

THE EDUCATIONAL DESIGN OF THIS activity addresses the needs of dermatologists, allergists/clinical immunologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe atopic dermatitis.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

Discuss atopic dermatitis pathophysiology, focusing on clinically relevant disease mechanisms, risk factors, and novel therapeutic targets

Comprehensively assess patients with atopic dermatitis to determine symptom severity, characterize potential phenotypes, identify comorbidities, and document treatment responses

Describe the clinical profiles of current and emerging biologic therapies for moderate-to-severe atopic dermatitis

Individualize therapy for moderate-to-severe atopic dermatitis to prevent outbreaks, maximize health-related quality of life, manage comorbidities, and minimize treatment-related adverse effects

Communicate with patients and, when necessary, caregivers to improve their understanding of atopic dermatitis and secondary complications, while facilitating shared decision-making

STATEMENT OF NEED/PROGRAM OVERVIEW

Atopic dermatitis is a chronic inflammatory condition with manifestations in the skin and in other organ systems throughout the body.1 Increasing in prevalence over the last 2 decades, the disease places tremendous burdens on patients, caregivers, and other family members.1,2 Our evolving understanding of disease pathophysiology and widespread effects on patient health and quality of life highlight the need for prompt diagnosis and proactive management.3,4 Moreover, research into the mechanisms underlying atopic dermatitis pathogenesis and progression has led to new approaches for disease characterization and treatment.5,6 The goal of this eHealth Source™ activity is to educate clinicians on atopic dermatitis pathoetiology, best practices in patient evaluations, and the clinical profiles of treatment options for moderate-to-severe disease, including a biologic therapy recently approved by the US Food and Drug Administration (FDA). With the overall goal of improving outcomes for patients with moderate-to-severe atopic dermatitis, this educational activity integrates published clinical data and the experience of expert faculty to provide actionable recommendations on individualizing care and improving patient-clinician communication.

REFERENCES

Nutten S. Atopic dermatitis: global epidemiology and risk factors.

Ann Nutr Metab.

2015:66(suppl 1):8-16.